Daniela Pugliese1, Marco Daperno2, Gionata Fiorino3, Edoardo Savarino4, Elena Mosso5, Livia Biancone6, Anna Testa7, Lucio Sarpi8, Maria Cappello9, Giorgia Bodini10, Flavio Caprioli11, Stefano Festa12, Gabriella Laino13, Giovanni Maconi14, Silvia Mazzuoli15, Giammarco Mocci16, Alessandro Sartini17, Alessandra D'Amore18, Stefano Alivernini19, Elisa Gremese19, Alessandro Armuzzi20. 1. IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. 2. Gastroenterology Unit, A.O. Ordine Mauriziano, Turin, Italy. 3. IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Italy. 4. Gastroenterology Unit, Department Surgery, Oncology and Gastroenterology, University of Padua, Italy. 5. General and Specialistic Medicine/Gastroenterology, Città della Salute e della Scienza di Torino, Italy. 6. University of Rome Tor Vergata, Department of Systems Medicine, Gastroenterology, Rome, Italy. 7. Federico II University, Gastroenterology, Naples, Italy. 8. Gastroenterologia ed Endoscopia Digestiva Aziendale USL Umbria1, Perugia, Italy. 9. Gastroenterology and Hepatology Section, DiBiMis, University of Palermo, Palermo, Italy. 10. Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. 11. Department of Pathophysiology and Transplantation, University of Milan and Gastroenterology and Endoscopy Unit, IRCCS Cà Granda, IRCCS Policlinico Hospital, Milan, Italy. 12. IBD Unit, San Filippo Neri Hospital, Rome, Italy. 13. Department of New Technologies and Translational Research in Medicine and Surgery, University of Pisa, Pisa, Italy. 14. Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy. 15. Gastroenterology Unit, San Nicola Pellegrino Hospital, Trani, Italy. 16. Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy. 17. Department of Internal Medicine, Gastroenterology Unit, University of Modena and Reggio Emilia, Modena, Italy. 18. Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy. 19. Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, Rome, Italy. 20. IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: alearmuzzi@yahoo.com.
Abstract
BACKGROUND: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. AIMS: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. METHODS: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. RESULTS: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. CONCLUSIONS: Subcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.
BACKGROUND: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. AIMS: to describe the outcomes of IBDpatients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. METHODS: This multicenter, retrospective study included all IBDpatients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. RESULTS: Seventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event. CONCLUSIONS: Subcutaneous ustekinumab had a good effectiveness profile for IBDpatients treated for concomitant dermatological or rheumatological conditions.
Authors: Anand Kumar; Dana Lukin; Robert Battat; Monica Schwartzman; Lisa A Mandl; Ellen Scherl; Randy S Longman Journal: J Gastroenterol Date: 2020-05-04 Impact factor: 7.527